NCT05877508View on ClinicalTrials.gov

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

July 29, 2024

Study Completion Date

July 31, 2025

Conditions
Long COVIDPost-Acute Sequela of COVID-19Post-Acute COVID-19
Interventions
DRUG

AER002

Intravenous infusion of AER002

OTHER

Placebo

Placebo infusion

Trial Locations (1)

94110

UCSF/Zuckerberg San Francisco General Hospital, San Francisco

Sponsors
All Listed Sponsors
collaborator

Aerium Therapeutics

UNKNOWN

collaborator

Patient-Led Research Collaborative

UNKNOWN

collaborator

PolyBio Research Foundation

OTHER

lead

Michael Peluso, MD

OTHER